SIRT1 activation promotes resistance of CML stem cells to tyrosine kinase inhibitors and acquisition of BCR-ABL mutations for acquired resistance. The gene discussed is SIRT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.